ViCentra Nets $85 Million in Series D Financing

ViCentra has closed an upsized $85 million Series D financing led by new investor Innovation Industries, a European deeptech venture capital firm. Other backing came from existing supporters Partners in Equity and Invest-NL, as well as EQT Life Sciences and Health Innovations.

ViCentra will use the money to accelerate manufacturing scale-up, launch the next-generation Kaleido 2 patch pump in Europe, and prepare for U.S. market entry.

“ViCentra is redefining insulin pump therapy with a platform that truly centers the user experience— combining clinical performance with design simplicity and wearability,” Innovation Industries Partner Caaj Greebe said. “At Innovation Industries, we invest in pioneering companies that blend world-class technology with clear commercial potential. ViCentra exemplifies this by delivering a next-generation system addressing the urgent need for better treatment options in diabetes care. We’re proud to lead this investment round and partner with Tom and the team as they deepen and expand their presence in Europe and prepare for U.S. entry.”

Kaleido is billed as the smallest, lightest, and most precise insulin patch pump that is discreet, intuitive, and personalized. Designed to feel more like personal technology than a traditional medical device, Kaleido features premium materials, and users can select their own favorite aluminum shells from a range of 10 preset color options. Integrated with Diabeloop’s self-learning automated insulin delivery algorithm and compatible with the Dexcom CGM sensor, Kaleido positions ViCentra at the forefront of next-generation diabetes care, helping reach many more users and improve the quality of life for people with diabetes, according to the company. Strong initial commercial uptake of Kaleido in Germany, France, and the Netherlands has driven demand beyond initial expectations. This financing enables ViCentra to scale the business for rapid revenue acceleration.

“Kaleido is a true disruptor—small, discreet, featherlight, and beautifully designed. It empowers people with diabetes by offering a more personal and distinctive choice in both function and style. Built with empathy and precision, it honors those who live with diabetes every day. With this funding, we can now meet surging European demand and fast-track our entry into the U.S. market. This is a pivotal moment for ViCentra and for the community we serve,” ViCentra CEO Tom Arnold stated.

The global insulin delivery market is one of the largest and fastest-growing medical device segments, driven by the rising prevalence of diabetes and increasing demand for solutions that blend clinical effectiveness with everyday usability. The insulin pump market alone is projected to reach more than $14 billion by 2034. Patch pumps represent the fastest-growing segment of the insulin delivery market, signaling a broader industry shift toward compact, wearable, and patient-centric solutions.

Kaleido aims to redefine wearable insulin delivery as the first insulin patch pump designed with the form, function, and simplicity of a lifestyle product. Kaleido is made from premium materials and offers users flexibility in the method in which and where they wear their pump, allowing people with diabetes to manage their therapy in ways that fit seamlessly into their daily lives. It delivers advanced, automated insulin therapy through seamless integration with Diabeloop’s clinically validated hybrid closed loop algorithms, DBLG1 and DBLG2.

ViCentra is striving to improve life with diabetes through empathetic innovation, simplicity, and design excellence. The company develops and manufactures the Kaleido insulin patch pump system, a flexible, discreet alternative to traditional insulin pumps. ViCentra is headquartered in Utrecht, the Netherlands.

Innovation Industries is a European deep tech venture capital firm with €1 billion in capital under management. The firm invests in visionary science and engineering-based companies that tackle the world’s most pressing challenges. Innovation Industries partners with entrepreneurs and researchers to turn scientific breakthroughs into transformative companies. The firm provides long-term capital and strategic support from lab to scale, actively bridging the gap between academia and industry through close collaboration with technical universities, research institutions, and industry partners. Innovation Industries has offices in Amsterdam, Eindhoven and Munich.

Partners in Equity is a private investment firm supporting companies and funds that create solutions to environmental challenges. The firm is building a portfolio of investments in sustainable agriculture and food systems, circularity, and climate solutions, while also continuing to support existing portfolio companies, including in healthcare. Founded in 2003, Partners in Equity has invested in a range of companies in different stages. The firm partners with organizations whose missions and values align with its own and remains committed for the long term.

Invest-NL is the National Promotional Institution of the Netherlands that aims to drive a sustainable and innovative future. It accelerates and finances major societal transitions in agrifood, biobased and circular economy, deep tech, energy, and life sciences and health. As a system player, Invest-NL connects entrepreneurs, financiers, knowledge institutions, and governments—both in the Netherlands and abroad. The Institution removes barriers, mobilizes capital, and helps develop emerging sectors.